KGKitty H. Gelberg

Kitty H. Gelberg

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kitty H. Gelberg has a total of 76 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Xylazine Test Strip Use Among People Who Use Drugs in New York State

    by Kitty H. Gelberg, Fernando Montero, Mingway Chang, Mary R. Msw Russo, Matthew R. Lootens, James L. David, Redonna Chandler, Emmanuel Oga, Louisa Gilbert, Nabila El-Bassel

    Objectives: Xylazine test strips (XTS) allow for rapid identification of xylazine in drugs, yet little is known about those using XTS. Therefore, this study explores the characteristics of people who use drugs (PWUDs) who use XTS and examines risk reduction behaviors associated with XTS use. Methods: This observational cohort study was conducted in New York between September and December 2023 as part of a larger study. Questions about XTS use were added to the parent study’s baseline survey of PWUDs and were completed by 254 PWUDs. Sociodemographic characteristics compared XTS users to nonusers. Propensity score weighting using inverse probability of treatment weights was used to examine the association of ever-using XTS with risk reduction behaviors and the drug type used. Results: Sixty-six participants (26%) had used XTS; 80% trusted the results, and 79% were confident in their ability to use XTS to detect xylazine. Those who had used XTS were more likely to have naloxone nearby (aOR=7.51, 95% CI: 2.26–24.95, P=0.001), use a test shot (aOR=2.43, 95% CI: 1.18–5.01, P=0.016), have someone check on them while using (aOR=2.52, 95% CI: 1.23–5.19, P=0.012), and watch someone use the same drugs (aOR=2.35, 95% CI: 1.19–4.65, P=0.014). XTS use was associated with using opioids (aOR=3.68, 95% CI: 1.38–9.81, P=0.009) and injecting drugs (aOR=4.32, 95% CI: 1.91–9.77, P<0.001). Conclusions: Our study demonstrates that XTS use appears to be associated with engaging in risk reduction behaviors, suggesting XTS can be a useful harm reduction tool. More research is needed to assess whether PWUDs change their drug consumption behaviors based on XTS results.


  • Open Access

    Association of fentanyl test strip results and change in drug use behaviors: A multi-state, community-based observational study

    by Kitty H. Gelberg, Nabila El-Bassel, Denise C. Babineau, Rachel A. Vickers-Smith, Laura C. Fanucchi, Janet E. Childerhose, Megan E. Hall, Megan E. Dzurec, Jennifer Villani, Mary R. Russo, et al.


  • Effect of the Communities That HEAL Intervention on Overdose Education and Naloxone Distribution: A Cluster-Randomized, Wait-List Controlled Trial

    by Patricia R. Freeman, Alexander Y. Walley, T. John Winhusen, Emmanuel A. Oga, Jennifer Villani, Timothy Hunt, Redonna K. Chandler, Douglas R. Oyler, Brittni Reilly, Kitty Gelberg, et al.

    Objectives. To determine whether the Communities That HEAL (CTH) intervention is effective in increasing naloxone distribution compared with usual care. Methods. The HEALing (Helping to End Addiction Long-Term) Communities Study (HCS) is a cluster-randomized, parallel-arm, wait-list controlled implementation science trial testing the impact of the CTH intervention on increasing the use of evidence-based practices to lower opioid-related overdose deaths. Communities (n = 67) highly impacted by opioid overdose in Kentucky, Massachusetts, New York, and Ohio were allocated to CTH intervention (n = 34) or wait-list comparison (usual care; n = 33) arms. The primary outcome for this study was the number of naloxone units distributed in HCS communities during the comparison period (July 1, 2021‒June 30, 2022), examined using an intent-to-treat negative binomial regression model. Results. Naloxone distribution was 79% higher in the CTH intervention versus usual care arm (adjusted relative rate = 1.79; 95% confidence interval = 1.28, 2.51; P = .001; adjusted rates of naloxone distribution 3378 vs 1884 naloxone units per 100 000 residents), when controlling for urban‒rural status, state, baseline opioid-related overdose death rate, and baseline naloxone distribution rate. Conclusions. The CTH intervention increased naloxone distribution compared with usual care in communities highly impacted by the opioid crisis. Trial Registration. ClinicalTrials.gov identifier: NCT04111939. ( Am J Public Health. 2025;115(1):83–94. https://doi.org/10.2105/AJPH.2024.307845 )


  • Open Access

    Need for Improved Timeliness of Reporting on Drug Overdose Fatalities: The HEALing Communities Study

    by Kitty H. Gelberg, Rachel Chase, Megan Lindstrom, Karli R. Hochstatter, Lauren Larochelle, Timothy Hunt

    Objective: Timely data on drug overdose deaths can help identify community needs, evaluate the effectiveness of interventions, and allocate resources. We identified variations in death investigation and reporting systems within and between states that affect the timeliness and accuracy of death certificate information. Methods: The HEALing Communities Study (HCS) is a community-engaged, data-driven approach to combating the opioid crisis in 67 communities in 4 states: Kentucky, Massachusetts, New York, and Ohio. HCS conducted a survey of coroners and medical examiners to understand variability in drug overdose death data. We compared survey results in Massachusetts, New York, and Ohio with national data to investigate the completeness of provisional death counts by type of death investigation system. Results: Communities in each HCS state had different ways of collecting and reporting mortality data. Completion of death certificates for drug overdoses ranged from <2 weeks in 23% (7 of 31) of those surveyed to more than 3 months in 10% (3 of 31) of those surveyed. Variabilities in the timeliness of reporting drug overdose deaths were not associated with type of coroner or medical examiner office in each state, urban versus rural setting, or specificity of drug information on the death certificate. Conclusion: Having specific drug information on the death certificate may increase death certificate quality, comparability, and accuracy. We recommend the following: (1) all coroners and medical examiners should be trained on conducting death investigations, interpreting toxicology reports, and completing death certificates; (2) 1 office in each state should oversee all coroners and medical examiners to increase data consistency; and (3) communities should identify and address barriers to timely death certification.


  • The impact of the national stay-at-home order on emergency department visits for suspected opioid overdose during the first wave of the COVID-19 pandemic

    by Elisabeth D. Root, Svetla Slavova, Marc LaRochelle, Daniel J. Feaster, Jennifer Villani, Jolene Defiore-Hyrmer, Nabila El-Bassel, Rosa Ergas, Kitty Gelberg, Rebecca Jackson, et al.